---
title: "Unichem Laboratories Ltd (UNICHEMLAB) — Share Price, Financials & Analysis"
symbol: "UNICHEMLAB"
company: "Unichem Laboratories Ltd"
canonical: "https://tapetide.com/stocks/UNICHEMLAB"
isin: "INE351A01035"
nse_symbol: "UNICHEMLAB"
bse_code: "506690"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 3735.38
generated_at: "2026-09-13T18:57:17.327Z"
---

# Unichem Laboratories Ltd (UNICHEMLAB)

Canonical page: https://tapetide.com/stocks/UNICHEMLAB

## Company

- **NSE Symbol:** UNICHEMLAB
- **BSE Code:** 506690
- **ISIN:** INE351A01035
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2001-02-07
- **CEO:** Mr. Pabitra Kumar Kalipada Bhattacharyya
- **Employees:** 3142
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** unichemlabs.com

## About

Unichem Laboratories Ltd is involved in pharmaceuticals
 in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

## Latest Price

- **Price:** ₹539.7
- **Change:** +7 (+1.31%)
- **Open:** ₹528.7
- **Day High:** ₹544.2
- **Day Low:** ₹522.05
- **Previous Close:** ₹532.7
- **Volume:** 59557
- **As Of:** 2026-09-11T10:23:51+00:00

## Key Fundamentals

Observed at 2026-09-11T04:46:05.230487Z.

- **Market Cap:** ₹3735.38 Cr
- **Classification:** Microcap
- **P/E (reported):** 12.3
- **P/E (TTM):** 12.47
- **EPS (TTM):** ₹43.29
- **EPS (reported):** ₹0
- **Book Value:** ₹385.97
- **Price to Book:** 1.38
- **Dividend Yield:** 0.75%
- **ROE:** 9.3%
- **ROCE:** 11.36%
- **Debt to Equity:** 0.18
- **Revenue (yearly):** ₹2264.9 Cr
- **Net Income:** ₹252.8 Cr
- **EBITDA:** ₹247.2 Cr
- **52-Week High:** ₹687.2
- **52-Week Low:** ₹278.2
- **RSI (14):** 47.81

## Tapetide Score

- **Score:** 54 / 100
- **Score date:** 2026-09-04
- **Archetype:** Cheap but Weak
- **What it means:** A low multiple sitting on weak financials. Worth establishing what the market is discounting before treating the low valuation as an opportunity — weak fundamentals often justify it.
- **Pillar profile:** Quality: Weak · Valuation: Cheap · Momentum: Rising
- **Percentile:** 65.6 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 58.51 | 9% |
| growth | 26.66 | 9% |
| momentum | 82.42 | 12% |
| ownership | 33.59 | 24% |
| quality | 37.17 | 22% |
| valuation | 89.16 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has delivered good profit growth of 25.0% CAGR over last 5 years

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 2.34% over last 3 years.
- Earnings include an other income of Rs.277 Cr.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 151.85% | -74% | 101.4% |
| ebitda margin growth | 45.58% | -21.94% | 67.48% | 19.61% |
| net income growth | 280.73% | 83.85% | 35% | 25% |
| revenue growth | 8.29% | 5.53% | 18% | 12% |
| roce | 97.34% | 66.81% | -561.79% | 2.1% |
| roe | 280.11% | 65.78% | 3.69% | 638.1% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 416 | 466 | 432 | 483 | 507 | 533 | 587 | 527 | 579 | 521 | 575 | 633 |
| Expenses | 407 | 435 | 406 | 443 | 452 | 448 | 503 | 504 | 513 | 476 | 527 | 563 |
| Operating Profit | 9 | 31 | 25 | 40 | 55 | 86 | 84 | 22 | 66 | 45 | 48 | 70 |
| OPM % | 2.1 | 7 | 6 | 8 | 11 | 16 | 14 | 4.3 | 11 | 9 | 8 | 11 |
| Other Income | 6 | 79 | -119 | 4 | 9 | 14 | 9 | 7 | -37 | 287 | 11 | 16 |
| Interest | 7 | 6 | 5 | 4 | 5 | 7 | 5 | 7 | 8 | 7 | 9 | 7 |
| Depreciation | 29 | 32 | 27 | 32 | 32 | 31 | 30 | 32 | 31 | 31 | 31 | 30 |
| Profit before tax | -22 | 73 | -126 | 8 | 27 | 62 | 58 | -9 | -11 | 293 | 19 | 49 |
| Tax % | 12 | 0 | 3 | 74 | 9 | 6 | 8 | 16 | 10 | 10 | 42 | 15 |
| Net Profit | -24 | 73 | -129 | 2 | 25 | 58 | 53 | -10 | -12 | 264 | 11 | 41 |
| EPS in Rs | -3.48 | 10.4 | -18.37 | 0.29 | 3.5 | 8.22 | 7.52 | -1.49 | -1.69 | 37.54 | 1.55 | 5.89 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 815 | 1180 | 1104 | 1235 | 1270 | 1343 | 1785 | 2111 | 2202 | 2308 |
| Expenses | 942 | 1254 | 1153 | 1144 | 1198 | 1389 | 1698 | 1846 | 2013 | 2079 |
| Operating Profit | -128 | -74 | -49 | 91 | 72 | -46 | 87 | 265 | 189 | 229 |
| OPM % | -16 | -6 | -4.5 | 7 | 6 | -3.4 | 4.9 | 13 | 9 | 10 |
| Other Income | 2735 | 91 | 91 | 50 | 47 | 0 | -26 | 35 | 260 | 277 |
| Interest | 8 | 8 | 8 | 5 | 6 | 17 | 23 | 21 | 32 | 32 |
| Depreciation | 51 | 67 | 82 | 84 | 91 | 113 | 123 | 125 | 125 | 123 |
| Profit before tax | 2548 | -58 | -48 | 51 | 22 | -176 | -85 | 155 | 292 | 350 |
| Tax % | 0 | -59 | 25 | 33 | -50 | 15 | 10 | 11 | 14 | — |
| Net Profit | 2545 | -24 | -60 | 34 | 33 | -202 | -94 | 138 | 253 | 305 |
| EPS in Rs | 361.82 | -3.38 | -8.55 | 4.87 | 4.7 | -28.72 | -13.32 | 19.53 | 35.91 | 43.29 |
| Dividend Payout % | 1 | -118 | -47 | 82 | 85 | -14 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 18 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 1045 | 2666 | 2606 | 2517 | 2543 | 2604 | 2421 | 2424 | 2437 | 2703 |
| Borrowings | 98 | 151 | 200 | 206 | 119 | 349 | 314 | 248 | 460 | 500 |
| Other Liabilities | 359 | 359 | 323 | 407 | 436 | 351 | 444 | 589 | 659 | 489 |
| Total Liabilities | 1521 | 3190 | 3142 | 3145 | 3112 | 3319 | 3193 | 3275 | 3569 | 3707 |
| Fixed Assets | 491 | 578 | 810 | 870 | 884 | 990 | 1257 | 1252 | 1300 | 1213 |
| CWIP | 250 | 238 | 92 | 330 | 568 | 494 | 147 | 123 | 31 | 100 |
| Investments | 14 | 901 | 926 | 550 | 392 | 264 | 2 | 1 | 0 | 0 |
| Other Assets | 766 | 1473 | 1313 | 1395 | 1269 | 1571 | 1787 | 1898 | 2239 | 2394 |
| Total Assets | 1521 | 3190 | 3142 | 3145 | 3112 | 3319 | 3193 | 3275 | 3569 | 3707 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 68 | -112 | -328 | 20 | 33 | -260 | -85 | 14 | -7 | 4 |
| Cash from Investing Activity | -132 | 1648 | -286 | -36 | -66 | 100 | 241 | 63 | -242 | 194 |
| Cash from Financing Activity | 59 | -881 | -2 | -62 | -121 | 191 | -81 | -106 | 184 | 2 |
| Net Cash Flow | -4 | 655 | -616 | -78 | -154 | 32 | 75 | -29 | -65 | 200 |
| Free Cash Flow | -79 | -271 | -519 | -360 | -254 | -386 | -123 | 0 | -142 | 163 |
| CFO/OP | -237 | 89 | 424 | -49 | 52 | -350 | 160 | 23 | 4 | 6 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 165 | 124 | 135 | 129 | 74 | 142 | 160 | 131 | 135 | 137 |
| Inventory Days | 397 | 278 | 278 | 374 | 518 | 527 | 414 | 365 | 418 | 349 |
| Days Payable | 297 | 230 | 182 | 236 | 202 | 161 | 193 | 174 | 164 | 128 |
| Cash Conversion Cycle | 265 | 172 | 231 | 267 | 390 | 508 | 382 | 322 | 389 | 358 |
| Working Capital Days | 174 | 133 | 165 | 154 | 163 | 207 | 207 | 173 | 159 | 169 |
| ROCE % | 9 | 128 | -2 | -2 | 2 | 1 | -5 | 0 | 6 | 4 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 70.21% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% | 70.22% |
| FIIs | 0.83% | 0% | 0.9% | 0.89% | 0.94% | 1.06% | 0.98% | 0.98% | 1% | 0.99% | 1% | 0.9% |
| DIIs | 10.32% | 9.29% | 11.27% | 11.58% | 11.67% | 11.63% | 11.32% | 10.92% | 10.75% | 10.74% | 10.63% | 10.46% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 15.8% | 15.63% | 15.12% | 14.8% | 14.58% | 14.47% | 14.8% | 15.16% | 15.26% | 15.18% | 15.22% | 15.59% |
| Others | 2.84% | 4.85% | 2.49% | 2.5% | 2.6% | 2.62% | 2.67% | 2.72% | 2.77% | 2.86% | 2.93% | 2.83% |
| No. of Shareholders | 21584 | 20877 | 21171 | 20621 | 20374 | 21472 | 21621 | 23010 | 23577 | 23267 | 23386 | 25347 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 5 / 6

### Moving Averages — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 551.12 | Sell |
| EMA (10) | 545.51 | Sell |
| SMA (20) | 540.49 | Sell |
| EMA (20) | 542.47 | Sell |
| SMA (50) | 544.03 | Sell |
| EMA (50) | 523.29 | Buy |
| SMA (100) | 470.91 | Buy |
| EMA (100) | 488.7 | Buy |
| SMA (200) | 427.96 | Buy |
| EMA (200) | 473.99 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 50.12 | Neutral |
| MACD (12,26,9) | 5.3 | Sell |
| Stochastic (14,3,3) | 39.35 | Neutral |
| ADX (14) | 31.97 | Buy |
| Williams %R (14) | -59.12 | Neutral |
| ATR (14) | 27.51 | High Volatility |
| ROC (12) | 1.77 | Buy |
| Stoch RSI (14) | 18.2 | Buy |
| UO (7,14,28) | 38.3 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Submitted Regulation 74(5) compliance certificate for quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8ad4d1b3-27c2-4248-a42d-97cbc980f380.pdf) |
| 6 May - Board meeting on May 22, 2026 to approve Q4 FY26 and FY26 financial results. | [Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended March 31, 2026, And Audited Financial Results (Standalone And Consolidated) For The Year Ended March 31, 2026. 6 May - Board meeting on May 22, 2026 to approve Q4 FY26 and FY26 financial results.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/88ef743f-754f-4a44-b01c-3595fbb8421b.pdf) |
| 6 Feb - Tax order disallowed ₹49.35 lakh ITC; demand ₹1.01 crore received 5 Feb 2026. | [Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 6 Feb - Tax order disallowed ₹49.35 lakh ITC; demand ₹1.01 crore received 5 Feb 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/17989177-a62a-4f77-9038-c9207d1a0e04.pdf) |
| 6 Feb - Results for the quarter and nine months ended December 31, 2025, published in the newspaper on February 6, 2026. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Feb - Results for the quarter and nine months ended December 31, 2025, published in the newspaper on February 6, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c924dac4-fccd-4926-b852-fbf6bd29956e.pdf) |
| 5 Feb - Approved Q3/9M results to Dec 31, 2025; consolidated Q3 PAT Rs.264.29 crore; appointed Dr. Swati Patankar. | [Announcement under Regulation 30 (LODR)-Change in Management 5 Feb - Approved Q3/9M results to Dec 31, 2025; consolidated Q3 PAT Rs.264.29 crore; appointed Dr. Swati Patankar.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3a27529e-d194-42e2-87e0-f9f5d8c33f4f.pdf) |
| 26 Feb - Ballot notice publication dated 26th February 2026. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 26 Feb - Ballot notice publication dated 26th February 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/414e12da-fef4-4449-8c64-73c391ad72fa.pdf) |
| 25 Feb - Postal ballot to appoint Dr. Swati Patankar; approve RPTs up to ₹400cr and ₹1,600cr; e-voting Feb26–Mar27,2026. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 25 Feb - Postal ballot to appoint Dr. Swati Patankar; approve RPTs up to ₹400cr and ₹1,600cr; e-voting Feb26–Mar27,2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8e7e337e-4392-41ea-8a08-da202daccc6e.pdf) |
| 24 Mar - Trading window closed from 1 Apr 2026 until 48 hours after results for quarter/year ended 31 Mar 2026. | [Closure of Trading Window 24 Mar - Trading window closed from 1 Apr 2026 until 48 hours after results for quarter/year ended 31 Mar 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a84b2782-ed8f-47d3-8edc-ab832f3383be.pdf) |
| 20 Mar - Independent director Priti Puri's three-year term ended 20 March 2026; board composition revised effective 21 March 2026. | [Announcement under Regulation 30 (LODR)-Change in Directorate 20 Mar - Independent director Priti Puri's three-year term ended 20 March 2026; board composition revised effective 21 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/05ee7941-df59-4d1f-b8b0-95b4cda94471.pdf) |
| 12 Apr - On 12 April 2026, Unichem's U.S. subsidiary recalled Buspirone Hydrochloride Tablets 5 mg due to OOS assay results. | [Announcement Under Reg. 30 - Product Recall 12 Apr - On 12 April 2026, Unichem's U.S. subsidiary recalled Buspirone Hydrochloride Tablets 5 mg due to OOS assay results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6ccfd91c-dcfb-4157-b98c-3a427056658a.pdf) |

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-26 | [Significant Increase In The Volume Of Securities.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=721255b9-e99d-4ece-bd9f-4047ab0de744.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dfeedcba-7397-4b7e-af24-1f535b7884fe.pdf) |
| 2026-08-12 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9283e0c-98af-4086-b06b-1cebc722366b.pdf) |
| 2026-08-11 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=875b4119-1319-4928-aaad-b3ceabe38792.pdf) |
| 2026-08-11 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3edd8a47-dac3-436e-b594-a4a2e0aa9c2f.pdf) |
| 2026-07-29 | [Disclosure Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6eead508-dde1-46be-b51e-4bebebd52dfa.pdf) |
| 2026-07-28 | [Board Meeting Intimation for To Inter-Alia Consider And Approve The Unaudited Financial Results (Consolidated And Standalone) For The Quarter Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61912429-d8f5-4eb7-8afb-4c0cb01ebaab.pdf) |
| 2026-07-10 | [Response To Clarification Sought On Price Movement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbddb15d-2a21-47e7-8bda-71f584901367.pdf) |
| 2026-07-08 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9b7ec52-cf9f-4b1b-b839-2a2f38218922.pdf) |
| 2026-07-06 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=feabdb66-c74a-4b56-b3fa-7ee4458b85b0.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-11 | [Q1 Financial Statement Of FY 2026-2027](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=865dbd8a-9228-4ae0-bd4d-5153bbf031c3.pdf) |
| 2026-05-22 | [Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7cda0452-8c9c-4d8e-bd9c-c829e8419a43.pdf) |
| 2026-02-05 | [Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=18c98b59-f73d-4fac-82da-61914d569b3b.pdf) |
| 2025-11-11 | [Financial Results For Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51e4e766-e94c-4dcd-835d-fc67225b7e08.pdf) |
| 2025-08-04 | [Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=933fe131-6d56-47f1-b8e9-97780fa5f7c5.pdf) |
| 2025-05-22 | [Results For Quarter And Year Ended 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c867020-3fc5-45fe-840e-ca4e1b1df7d1.pdf) |
| 2025-02-06 | [Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=332a86b6-58b3-4b12-a100-764562e6b799.pdf) |
| 2024-08-08 | [Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c545a44-a625-4865-8a95-e4761a8eced3.pdf) |
| 2024-05-22 | [Financial Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=45a9ba00-f5b7-41ae-8b78-a471d5f14327.pdf) |
| 2024-02-05 | [Board Meeting Outcome for Outcome Of Board Meeting For Quarter And Nine Months Ended 31St December 2023.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c93664cd-8b0d-4a81-b529-157c654e4495.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2012 from nse](https://archives.nseindia.com/annual_reports/AR_UNICHEMLAB_2011_2012_18102012054141.zip) |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b195337a-998c-4207-bfa2-b35fe00033cf.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/455e5c8f-0956-41ec-a5c6-21c6957372d7.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e721c2ee-4c57-4431-8dc7-a71526015abc.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0d1c07f7-36dc-4f07-b3cf-a3ab21f980f0.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/506690/73645506690.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/506690/68721506690.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/506690/5066900320.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/506690/5066900319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/506690/5066900318.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Jun 2017 | [Concall - Jun 2017](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00caf778-7c08-45d5-954f-b7bf308a4dc5.pdf) |
| Jun 2017 | [Concall - Jun 2017](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2017/6/00caf778-7c08-45d5-954f-b7bf308a4dc5.pdf) |
| Jun 2016 | [Concall - Jun 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=AA4E0AEA_4D16_4F90_8465_009E2F3E36D3_132734.pdf) |
| Aug 2016 | [Concall - Aug 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8C41D1AD_DD8E_4D40_B3A3_B5FA8DB7BA09_142305.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:57:17.327Z.